Presage Biosciences Adds Board Member
Executive Summary
The oncology company Presage Biosciences has appointed David Johnson to its board of directors. With 25 years’ experience Johnson joins Presage from the oncology focused company, Acerta Pharma, where he was CEO. He has held roles with increasing responsibilities within clinical development, medical affairs, pipeline development, and commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche.